TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice

Oncogene

Volumn 32, Issue 18, 2013, Pages 2273-2281

  Li, A ^a,b   Zhang, C ^a   Gao, S ^a,c   Chen, F ^a,b   Yang, C ^a   Luo, R ^b   Xiao, H ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Michigan State University   (United States)

Author keywords

EGFR signaling; IP30; lung adenocarcinoma; tumor suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDES AND PROTEINS; PROTEIN KINASE B; TAT INTERACTING PROTEIN 30; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; ENDOSOME; GENE; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TIP30 GENE;

ACETYLTRANSFERASES; ADENOCARCINOMA; ADENOMA; ANIMALS; CELL NUCLEUS; CYTOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STEM CELLS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84877575545     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.253     Document Type: Article

References (42)

1. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005; 65: 10280-10288.
2. Tchou-Wong KM, Jiang Y, Yee H, LaRosa J, Lee TC, Pellicer A et al. Lung-specific expression of dominant-negative mutant p53 in transgenic mice increases spontaneous and benzo(a)pyrene-induced lung cancer. Am J Respir Cell Mol Biol 2002; 27: 186-193.
3. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001; 15: 3249-3262.
4. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
5. Ehrhardt A, Bartels T, Geick A, Klocke R, Paul D, Halter R. Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes. Br J Cancer 2001; 84: 813-818.
6. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9: 485-495.
7. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20: 1496-1510.
8. Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A et al. Identification of DOK genes as lung tumor suppressors. Nat Genet 2010; 42: 216-223.
9. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
10. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379-2385.
11. Gazdar AF, Minna JD. Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev Res (Phila) 2008; 1: 156-160.
12. Shtivelman E. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 1997; 14: 2167-2173.
13. Xiao H, Tao Y, Greenblatt J, Roeder RG. A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription. Proc Natl Acad Sci USA 1998; 95: 2146-2151.
14. Ito M, Jiang C, Krumm K, Zhang X, Pecha J, Zhao J et al. TIP30 deficiency increases susceptibility to tumorigenesis. Cancer Res 2003; 63: 8763-8767.
15. Zhao J, Ni H, Ma Y, Dong L, Dai J, Zhao F et al. TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and P53 expression. Hu Pathol 2007; 38: 293-298.
16. Chen X, Cao X, Dong W, Luo S, Suo Z, Jin Y. Expression of TIP30 tumor suppressor gene is down-regulated in human colorectal carcinoma. Dig Dis Sci 2006; 55: 2219-2226.
17. Tong X, Li K, Luo Z, Lu B, Liu X, Wang T et al. Decreased TIP30 Expression Promotes Tumor Metastasis in Lung Cancer. Am J Pathol 2009; 174: 1931-1939.
18. Pecha J, Ankrapp D, Jiang C, Tang W, Hoshino I, Bruck K et al. Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland. Oncogene 2007; 26: 7423-7431.
19. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835.
20. Zhang C, Mori M, Gao S, Li A, Hoshino I, Aupperlee MD et al. Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors. Cancer Res 2010; 70: 10224-10233.
21. Zhang C, Li A, Zhang X, Xiao H. A novel TIP30 protein complex regulates EGF receptor signaling and endocytic degradation. J Biol Chem 2011; 286: 9373-9381.
22. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14: 822-827.
23. Chen V, Shtivelman E. CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation. Cell Cycle 2010; 9: 4941-4953.
24. Fong S, King F, Shtivelman E. CC3/TIP30 affects DNA damage repair. BMC Cell Biol 2010; 11: 23.
25. Xiao H, Palhan V, Yang Y, Roeder RG. TIP30 has an intrinsic kinase activity required for up-regulation of a subset of apoptotic genes. EMBO J 2000; 19: 956-963.
26. Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H. TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem 2004; 279: 27781-27789.
27. King FW, Shtivelman E. Inhibition of nuclear import by the proapoptotic protein CC3. Mol Cell Biol 2004; 24: 7091-7101.
28. Zhao J, Lu B, Xu H, Tong X, Wu G, Zhang X et al. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma. Hepatology 2008; 48: 265-275.
29. Lin S-Y, Makino K, Xia W, Matin A, Wen Y, Kwong KY et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-808.
30. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 2006; 8: 1359-1368.
31. Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007; 21: 1731-1746.
32. Morimoto M, Kopan R. rtTA toxicity limits the usefulness of the SP-C-rtTA transgenic mouse. Dev Biol 2009; 325: 171-178.
33. Yanagi S, Kishimoto H, Kawahara K, Sasaki T, Sasaki M, Nishio M et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J Clin Invest 2007; 117: 2929-2940.
34. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
35. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
36. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest 2007; 117: 2740-2750.
37. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant nonsmall-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
38. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
39. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008; 26: 2745-2753.
40. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
41. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004; 64: 2307-2316.
42. Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci 2010; 123: 1716-1723.